| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032346363 |
| P356 | DOI | 10.1186/1471-2180-12-41 |
| P932 | PMC publication ID | 3362776 |
| P698 | PubMed publication ID | 22439788 |
| P5875 | ResearchGate publication ID | 221968631 |
| P2093 | author name string | Vivek Daniel Paul | |
| Bharathi Sriram | |||
| Ravisha Chikkamadaiah | |||
| Juliet Mohan Raj | |||
| Nagalakshmi Narasimhaswamy | |||
| Aradhana A Vipra | |||
| Panchali Roy | |||
| Raghu Patil | |||
| Srividya Narayanamurthy Desai | |||
| P2860 | cites work | Bacteriophage Therapy: Exploiting Smaller Fleas | Q22061837 |
| Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers | Q24241136 | ||
| Pathogenesis of methicillin-resistant Staphylococcus aureus infection | Q24657579 | ||
| Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model | Q24682172 | ||
| Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks | Q24683675 | ||
| Staphylococcal vaccines and immunotherapy: to dream the impossible dream? | Q30355875 | ||
| Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group | Q31797996 | ||
| Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve | Q33181940 | ||
| Coagulase-negative staphylococci: role as pathogens | Q33540265 | ||
| Evolutionary analyses of Staphylococcus aureus identify genetic relationships between nasal carriage and clinical isolates | Q33808915 | ||
| Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus | Q33938244 | ||
| Development and characterization of a Staphylococcus aureus nasal colonization model in mice. | Q34001970 | ||
| A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein | Q34045132 | ||
| The role of nasal carriage in Staphylococcus aureus infections | Q34470454 | ||
| A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs | Q34758093 | ||
| Bacteriophage endolysins--current state of research and applications | Q36175326 | ||
| Bacteriophage lytic enzymes: novel anti-infectives | Q36242302 | ||
| Virulence determinants in Staphylococcus aureus and their involvement in clinical syndromes. | Q36286486 | ||
| Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates | Q36492132 | ||
| Update on clinical significance of coagulase-negative staphylococci | Q36640978 | ||
| Diversity of staphylococcal cassette chromosome mec structures in methicillin-resistant Staphylococcus epidermidis and Staphylococcus haemolyticus strains among outpatients from four countries | Q37072089 | ||
| Lysostaphin: an antistaphylococcal agent | Q37209589 | ||
| Isolation of methicillin-resistant coagulase-negative staphylococci from patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and comparison of different molecular techniques for discriminating isolates of Staphylococcus epidermidis | Q44306316 | ||
| Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. | Q46034505 | ||
| Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections | Q46695223 | ||
| Methods for determining the composition of nasal fluid by X-ray microanalysis | Q48031388 | ||
| Therapeutic use of bacteriophages. | Q53886967 | ||
| Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance | Q71616583 | ||
| Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery | Q72353232 | ||
| Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin | Q79281958 | ||
| FDA approves use of bacteriophages to be added to meat and poultry products | Q79305444 | ||
| P921 | main subject | bacteriophage | Q165028 |
| P304 | page(s) | 41 | |
| P577 | publication date | 2012-03-22 | |
| P1433 | published in | BMC Microbiology | Q15759430 |
| P1476 | title | Antistaphylococcal activity of bacteriophage derived chimeric protein P128 | |
| P478 | volume | 12 |
| Q27304933 | A chimeolysin with extended-spectrum streptococcal host range found by an induced lysis-based rapid screening method |
| Q37571286 | A novel chimeric lysin with robust antibacterial activity against planktonic and biofilm methicillin-resistant Staphylococcus aureus |
| Q40526792 | Antibiofilm Activity and Synergistic Inhibition of Staphylococcus aureus Biofilms by Bactericidal Protein P128 in Combination with Antibiotics |
| Q26781115 | Antimicrobial bacteriophage-derived proteins and therapeutic applications |
| Q38044739 | Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. |
| Q30234522 | Bacteriophages and Their Immunological Applications against Infectious Threats. |
| Q34298267 | Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128. |
| Q34649978 | Does the nose know? An update on MRSA decolonization strategies |
| Q51005740 | Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma: potential applications. |
| Q40192368 | Efficient Killing of Planktonic and Biofilm-Embedded Coagulase-Negative Staphylococci by Bactericidal Protein P128. |
| Q34349552 | Engineered bacteriophage lysins as novel anti-infectives |
| Q35871785 | Fighting sinus-derived Staphylococcus aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme |
| Q38542711 | Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. |
| Q59128002 | Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials |
| Q52679093 | Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care. |
| Q42126654 | Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128: Comparison to recombinant lysostaphin |
| Q51878166 | Staphylococcus bacteriophage tails with bactericidal properties: new findings. |
| Q35751036 | Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance. |
| Q57072119 | Turning a new phage |
| Q84860743 | Use of prophage free host for achieving homogenous population of bacteriophages: new findings |
Search more.